EMT Biopharma: Targeting agressive drug-resistant tumor cells
EMT-Biopharma has developed an entirely new approach to attack the most aggressive drug-resistant cancers. We identified a new cell surface complex that specifically appears on highly aggressive tumors that progress and/or develop drug resistance.
Fibrozumab was developed to target this complex — and in doing so can reprogram aggressive tumor cells to a less aggressive, drug-sensitive state.
EMT-Biopharma has developed an entirely new approach to attack the most aggressive drug-resistant cancers. We identified a new cell surface complex that specifically appears on highly aggressive tumors that progress and/or develop drug resistance.
Fibrozumab was developed to target this complex — and in doing so can reprogram aggressive tumor cells to a less aggressive, drug-sensitive state.
Fibrozumab represents a Cancer Cell State Reprogrammer that recognizes a wide range of cancers, where we expect it to reverse resistance to standard-of-care therapeutics.
Fibrozumab was engineered to function as a macrophage-myeloid cell engager which significantly amplifies its anti-tumor activity.
As a second mechanism, Fibrozumab also targets cancer-associated fibroblasts and angiogenic endothelial cells, where it reverses cancer-related fibrosis and angiogenesis. Fibrosis and angiogenesis represent host responses that promote the growth and metastasis of most — if not all — solid tumors.
Fibrozumab
Lead bispecific antibody · pre-IND
Two Markers
Epithelial cancers and fibrosis
Three Mechanisms
Anti-tumor · Anti-fibrotic · Anti-angiogenic
Fibrozumab: a human bispecific antibody targeting drug-resistant cell population
Fibrozumab: a human bispecific antibody targeting drug-resistant cell population
Fibrozumab is a bispecific antibody designed to target both surface integrins at once.
Its Fc domain also activates macrophages, which destroy the antibody-marked cells.
EMT Bio scientists discovered a way to use Fibrozumab’s unique ability to target the integrin-fibronectin complex on the surface of cancer cells.
Fibrozumab targeting fibrotic cancers: breast cancer and pancreatic cancer.
Also, Fibrozumab targeting fibrotic lung and liver diseases.
Stephen J. McCormack, PhD
CEO & Co-Founder
Veteran biotech operator. Built MannKind ($2B), CytomX ($1.5B), AlleCure (ALK exit), NeuroSystec, Pixium Vision (now Science Corp).
David Cheresh, PhD
Scientific Founder & Advisor
UCSD Pathology Vice Chair. Developed Unituxin (FDA 2015). TargeGen founder (Fedratinib FDA 2019, $7B exit). 26 issued patents.
Sara Weis, PhD
VP of Research & Co-Founder
Drives discovery, translational biology, and the Fibrozumab IND-enabling research roadmap.
Kamal Egodage, PhD
Chief Manufacturing Officer
Leads CMC, biologics process development, scale-up and clinical supply for Fibrozumab.
Doug Frankel
Organizational Development Advisor
Executive Vice President, National Search Associates.
Alfred Atallah, Esq.
Legal Advisor
Heads corporate, IP, and transactional matters supporting financing, patents, and partnerships.